A new market research report by Future Market Insights on the atopic dermatitis treatment market includes global industry analysis 2014–2021 and opportunity assessment 2022–2029. The report investigates the atopic dermatitis treatment market and provides critical insights for the forecast period of 2022-2029. As per the findings of the report, the global atopic dermatitis treatment market is projected to experience significant growth over the forecast period, due to increasing prevalence, promising pipeline molecules, higher treatment compliance, increasing access to treatment medication in developing countries, favorable reimbursement policies, increasing government support for research and development, and advancing technology.
The Global Atopic Dermatitis Treatment Market was valued at US$ 5.2 Bn in 2021 and is expected to reach US$ 7.6 Bn by 2029, finds Future Market Insights (FMI) in a recent market survey.
Corticosteroids Remain the Drug of Choice
Corticosteroids are referred as the first choice of treatment for the inflammation and pain relief. These medications are known to have effects, for example, decreasing tingling, allergic reaction, swelling and redness.
Request a report sample to gain comprehensive insights at
Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which ‘hydrocortisone’ is considered as the first. In addition, increasing innovations have resulted in the advent of topical non-corticosteroids immunomodulators and target medications, for example, immunomodulators such as pimecrolimus and tacrolimus, which in turn, is likely to fuel the growth of the atopic dermatitis treatment market. Moreover, topical corticosteroids are expected to play an important roles in the atopic dermatitis treatment.
|Data Points||Market Insights|
|Market Value 2021||USD 5.2 Bn|
|Market Value 2029||USD 7.6 Bn|
|Share of Top 5 Countries||52.1%|
|Key Players||The key players in the Atopic Dermatitis Treatment market are Sanofi SA, Galderma SA, Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Astellas Pharma Inc., Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Valeant Pharmaceutical International Inc.|
North America to Offer High Sales Opportunities
Growth prospects of the atopic dermatitis treatment market are likely to be high in North America over the forecast period of 2022-2029. Factors such as, greater treatment awareness among the patient population across the United States and Canada, early adoption of novel prescriptions, advanced healthcare infrastructure, better and favorable reimbursement policies, and increasing business associations of pharmaceutical organizations with contract research organizations in developing markets will continue to propel the atopic dermatitis treatment market growth. Despite the fact that the U.S and Canada deal with heavy investment in healthcare infrastructure as well as per capita expenditure, there are increasing number of campaigns organized each year by specific establishments, for example, National Eczema Associations, the PAN Foundation, and pharmaceutical organizations, which are envisaged to work to the advantage of several market vendors.
For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-3097
Hospital Pharmacies – The Key Distribution Channel for Atopic Dermatitis Treatment
Sales of medication for atopic dermatitis treatment through hospital pharmacies will continue to account for relatively high share in the market, as they can stock large range of prescription medicines, including progressively specific and investigational medications. Hospital pharmacies may provide a tremendous amount of medications every day, which is distributed to wards and to intensive care units as per the patient’s prescription schedule.
Topical Drug Administration- A Preferred Mode
Topical mode of administration remains highly preferred among the patient pool of atopic dermatitis. Advent of topical non-corticosteroids immunomodulators is the major factor for the growth in the demand for atopic dermatitis treatment. As topical administration gains prominence, major corticosteroids medications are formulated as topical, in addition to their benefits over oral dosage form.
Atopic Dermatitis Treatment Market: Vendor Insights
The report highlights some of the prominent market players, who have established themselves as leaders in the global atopic dermatitis treatment market. Some of the examples of key players in the global atopic dermatitis treatment market are Sanofi S.A., Galderma S.A., Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals Inc., Astellas Pharma, Inc., Anacor Pharmaceuticals, Inc., Regeneron Pharmaceuticals, and Valeant Pharmaceuticals International, Inc.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-3097
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain
Canine Atopic Dermatitis Treatment Market – The global Canine Atopic Dermatitis Treatment Market is estimated to exceed US$ 2.37 Bn by the end of 2029. Growing emphasis on the development of novel therapeutics such as monoclonal antibodies for the treatment of atopic dermatitis in dogs and cats is expected to favor the growth in the market.
Feline Atopic Dermatitis Treatment Market – Feline atopic dermatitis is the inflammation of the skin seen in the cats. Feline atopic dermatitis is often triggered by causative allergens which are either inhaled or through skin contact leading to inflammation of the skin.
Traumatic Brain Injuries Treatment Market – Each year traumatic brain injuries (TBI) contribute a substantial number of cases worldwide. TBI can be defined as an injury to the brain resulting from externally inflicted trauma resulting in damage to the brain cells and blood vessels.
Allergy Treatment Market – An allergy is a heightened sensitivity of immune system. Allergy occurs when a foreign substance which is harmless in nature reacts with immune system. These foreign substances are called allergens.
Substance Use Disorder Treatment Market – According to World Health Organization (WHO), the leading cause of disability around the world is not a physical disease, but a serious mood disorder known as depression. Around 350 million people suffer from depression worldwide, and that only about 50% of these individuals will ever receive treatment.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: email@example.com
For Media Enquiries: firstname.lastname@example.org